iifl-logo

Sun Pharmaceuticals Industries Ltd Profit & Loss Statement

1,832.3
(1.48%)
Apr 30, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

15,585.98

14,116.05

12,531.93

7,923.84

yoy growth (%)

10.41

12.64

58.15

3.12

Raw materials

-5,650.39

-5,107.48

-4,567.72

-3,492.77

As % of sales

36.25

36.18

36.44

44.07

Employee costs

-2,000.78

-1,805.98

-1,702.77

-1,617.69

As % of sales

12.83

12.79

13.58

20.41

Other costs

-5,027.29

-4,945.58

-3,549.79

-2,690.36

As % of sales (Other Cost)

32.25

35.03

28.32

33.95

Operating profit

2,907.52

2,257.01

2,711.65

123.02

OPM

18.65

15.98

21.63

1.55

Depreciation

-1,349.95

-1,236.43

-561.56

-432.23

Interest expense

-388.1

-267.52

-408.01

-388.31

Other income

957.92

192.07

1,510.92

1,128.04

Profit before tax

2,127.39

945.13

3,253

430.52

Taxes

-406.85

-13.17

-41.86

25.39

Tax rate

-19.12

-1.39

-1.28

5.89

Minorities and other

0

0

0

0

Adj. profit

1,720.54

931.96

3,211.14

455.91

Exceptional items

-1,820.53

-89.56

0

-950.5

Net profit

-99.99

842.4

3,211.14

-494.59

yoy growth (%)

-111.86

-73.76

-749.25

2,065.45

NPM

-0.64

5.96

25.62

-6.24

Sun Pharma.Inds. : related Articles

Sun Pharma’s MM-II Trial Shows Long-Lasting Relief for Knee Osteoarthritis
26 Apr 2025|01:15 PM

Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.

Read More
Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million
10 Mar 2025|10:46 AM

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

Read More
Sun Pharma Q3 Profit Jumps 19% YoY, Declares ₹10.50 Dividend
31 Jan 2025|10:17 PM

An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.

Read More
Sun Pharma reports Q2 net profit at ₹3,040 Crore
29 Oct 2024|10:30 AM

Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.

Read More
Sun Pharma's Hair Loss Drug Approved by USFDA
26 Jul 2024|01:45 PM

The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.

Read More
Mayne Pharma Sues Sun Pharma in Patent Dispute
25 Jul 2024|11:57 AM

IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.

Read More
USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|11:24 AM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.